Jingwu Zang

This inventor holds 17 USPTO granted patents and 8 published patent applications, plus 7 CIPO patents and 4 EPO patents. Top assignees: I-Mab Biopharma US Limited, I-Mab, I-Mab Biopharma (Hangzhou) Co., Ltd.. Active years: 2010-2024.

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 88.2

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 12)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 30(Granted Patents)

Company Filing History:

7 out of 14

I-Mab Biopharma US Limited

I-Mab Biopharma (Hangzhou) Co., Ltd.

patents

4. 2 out of 2

I-Mab Biopharma Co., Ltd.

patents

5. 1 out of 617

Baylor College of Medicine

patents

6. 1 out of 2

Opexa Therapeutics, Inc.

patents

Years Active: 2010-2024

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091467 - CD47 monoclonal antibodies and uses thereof (2024-09-17),

2. 11926662 - Anti-GM-CSF antibodies and uses thereof (2024-03-12),

3. 11613577 - Anti-CD73 antibodies and uses thereof (2023-03-28),

4. 11414485 - Anti-LAG-3 antibodies and uses thereof (2022-08-16),

5. 11401331 - Anti-PD-L1 antibody and IL-7 fusions (2022-08-02),

6. 11220546 - Anti-PD-L1 antibodies and uses thereof (2022-01-11),

7. 11034771 - Anti-CD73 anti-PD-L1 bispecific antibodies (2021-06-15),

8. 10973853 - Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof (2021-04-13),

9. 10889641 - Anti-GM-CSF antibodies and uses thereof (2021-01-12),

10. 10723799 - Anti-PD-L1 antibodies and uses thereof (2020-07-28),

11. 10647767 - Anti-GM-CSF antibodies and uses thereof (2020-05-12),

12. 10584169 - Anti-CD73 antibodies and uses thereof (2020-03-10),

13. 10577421 - Anti-LAG-3 antibodies and uses thereof (2020-03-03),

14. 10208119 - Anti-PD-L1 antibodies and uses thereof (2019-02-19),

15. 10059769 - Anti-PD-L1 antibodies and uses thereof (2018-08-28),

Title: The Innovative Contributions of Jingwu Zang

Introduction

Jingwu Zang is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biotechnology. With a total of 17 patents to his name, Zang has made remarkable advancements in the development of therapeutic antibodies.

Latest Patents

Among his latest patents, Zang has developed novel CD47 monoclonal antibodies and their uses. This invention provides antibodies or immunologically active fragments that exhibit low immunogenicity in humans, minimizing red blood cell depletion and hemagglutination. Additionally, he has created pharmaceutical compositions containing these antibodies for treating diseases mediated by CD47, as well as for inhibiting phagocytosis and platelet aggregation. Another notable patent includes anti-GM-CSF antibodies and their uses, which encompass humanized antibodies and fragments. These antibodies are intended for therapeutic, diagnostic, and prognostic purposes, particularly in treating inflammatory and autoimmune diseases.

Career Highlights

Zang has worked with notable companies such as I-Mab Biopharma US Limited and I-Mab, where he has contributed to groundbreaking research and development in the field of immunotherapy. His work has been instrumental in advancing the understanding and treatment of various diseases.

Collaborations

Zang has collaborated with esteemed colleagues, including Lei Fang and Zhengyi Wang, to further enhance the impact of his research and innovations.

Conclusion

Jingwu Zang's contributions to biotechnology through his innovative patents and collaborations have positioned him as a leading figure in the field. His work continues to pave the way for new therapeutic approaches and advancements in medical science.